Search results for "IMV"

showing 10 items of 60 documents

Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers.

2014

Background: The objective of this study is to determine whether simvastatin consumption and hyperlipidemia are associated with a worse periodontal condition and specific bone activity biomarkers. Methods: This cross-sectional and analytic study includes 73 patients divided into three groups: 1) simvastatin-treated patients with hyperlipidemia (n = 29); 2) patients with hyperlipidemia treated by diet alone (n = 28); and 3) normolipidemic patients (controls, n = 16). The periodontal clinical variables of all participants were gathered, a blood sample was drawn from each to determine the lipid profile (total cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein), se…

AdultMalemedicine.medical_specialtySimvastatinAlcohol DrinkingOsteocalcinHyperlipidemiasBlood SedimentationCollagen Type IBone remodelingN-terminal telopeptideInternal medicineHyperlipidemiaPeriodontal Attachment LossmedicineHumansTriglyceridesAgedHypolipidemic AgentsPeriodontitismedicine.diagnostic_testbusiness.industryCholesterol HDLSmokingOsteoprotegerinnutritional and metabolic diseasesCholesterol LDLMiddle Agedmedicine.diseasePeptide FragmentsEndocrinologyC-Reactive ProteinCholesterolCross-Sectional StudiesClinical attachment lossSimvastatinErythrocyte sedimentation ratePeriodonticsFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsPeriodontal IndexbusinessLipid profilePeptidesBiomarkersProcollagenmedicine.drugJournal of periodontology
researchProduct

Ezetimibe alone or in combination with simvastatin increases small, dense low-density lipoproteins in healthy men: a randomized trial

2010

Aims The predominance of small dense low-density lipoproteins (sdLDLs) has been associated with increased cardiovascular risk. The effect of ezetimibe on LDL subfraction distribution has not been fully elucidated. This study assessed by gradient gel electrophoresis the effects of ezetimibe alone, simvastatin alone, and their combination on sdLDL subfraction distribution. Methods and results A single-centre, randomized, parallel three-group open-label study was performed in 72 healthy men with a baseline LDL-cholesterol (LDL-C) concentration of 111 ± 30 mg/dL (2.9 ± 0.8 mmol/L). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24), or their combination ( n = …

AdultMalemedicine.medical_specialtySimvastatinRandomizationCombination therapyAdolescent10265 Clinic for Endocrinology and Diabetology610 Medicine & health2705 Cardiology and Cardiovascular Medicinelaw.inventionYoung AdultRandomized controlled trialEzetimibelawInternal medicinemedicineDistribution (pharmacology)HumansDrug Interactionsbiologybusiness.industryAnticholesteremic AgentsLipoprotein(a)Middle AgedEzetimibeLipoproteins LDLEndocrinologySimvastatinMultivariate Analysisbiology.proteinAzetidineslipids (amino acids peptides and proteins)Drug Therapy CombinationElectrophoresis Polyacrylamide GelatherosclerosisCardiology and Cardiovascular MedicinebusinessBody mass indexmedicine.drug
researchProduct

Cataracts and statins. A disproportionality analysis using data from VigiBase.

2019

The basis of the association between statin use and cataract has been explored using the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) through January 2019. The reporting odds ratios (RORs) as a measure of disproportionality for reported cataracts and individual statins have been calculated. Subgroup analyses according statin lipophilicity, sex, and age groups have been performed. Moreover, RORs have been calculated for non-statin lipid lowering drugs. An increased disproportionality have been found for most individual statins lovastatin: [ROR: 14.80, 95% confidence interval (CI): 13.30, 16.46)], atorvastatin (ROR: 3…

AdultMalemedicine.medical_specialtyStatinAdolescentmedicine.drug_classAtorvastatin010501 environmental sciencesToxicology030226 pharmacology & pharmacy01 natural sciencesRisk AssessmentCataract03 medical and health sciencesPharmacovigilanceYoung Adult0302 clinical medicineEzetimibeInternal medicinemedicineOdds RatioAdverse Drug Reaction Reporting SystemsHumansRosuvastatinChild0105 earth and related environmental sciencesAgedAged 80 and overbusiness.industryIncidenceGeneral MedicineOdds ratioMiddle AgedSimvastatinFemaleDrug MonitoringHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatinRegulatory toxicology and pharmacology : RTP
researchProduct

Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials

2015

Statin therapy may lower plasma coenzyme Q10 (CoQ10) concentrations, but the evidence as to the significance of this effect is unclear. We assessed the impact of statin therapy on plasma CoQ10 concentrations through the meta-analysis of available RCTs. The literature search included selected databases up to April 30, 2015. The meta-analysis was performed using either a fixed-effects or random-effect model according to I(2) statistic. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). The data from 8 placebo-controlled treatment arms suggested a significant reduction in plasma CoQ10 concentrations following treatment with statins (WMD: -0.44 μmol/…

AdultMalemedicine.medical_specialtyUbiquinoneAtorvastatinPharmacologyPlaceboGastroenterologychemistry.chemical_compoundDouble-Blind MethodInternal medicineHumansMedicineRosuvastatinClinical significanceAgedRandomized Controlled Trials as TopicPharmacologyCoenzyme Q10business.industryMiddle AgedPlacebo EffectConfidence intervalchemistrySimvastatinCase-Control StudiesFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugPharmacological Research
researchProduct

Comparison of UV and charged aerosol detection approach in pharmaceutical analysis of statins

2009

Abstract CAD (charged aerosol detector) has recently become a new alternative detection system in HPLC. This detection approach was applied in a new HPLC method for the determination of three of the major statins used in clinical treatment—simvastatin, lovastatin and atorvastatin. The method was optimized and the influence of individual parameters on CAD response and sensitivity was carefully studied. Chromatography was performed on a Zorbax Eclipse XDB C18 (4.6 mm × 75 mm, 3.5 μm), using acetonitrile and formic acid 0.1% as mobile phase. The detection was performed using both CAD (20 pA range) and DAD (diode array detector—238 nm) simultaneously connected in series. In terms of linearity, …

AerosolsSimvastatinAccuracy and precisionChromatographyChemistryFormic acidDetectorAnalytical chemistryLinearityCADHigh-performance liquid chromatographyAnalytical Chemistrychemistry.chemical_compoundEquipment and SuppliesHeptanoic AcidsWide dynamic rangeAtorvastatinPyrrolesLovastatinHydroxymethylglutaryl-CoA Reductase InhibitorsQuantitative analysis (chemistry)Chromatography High Pressure LiquidTabletsTalanta
researchProduct

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with …

2012

Aims The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg across subgroups of subjects with (n = 617) and without (n = 191) metabolic syndrome (MetS). Methods This was a post hoc analysis of a randomized, double-blind, 6-week study of adults 18–79 years with cardiovascular disease and diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. The percent change in LDL-C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed. Results In subjects with M…

Blood GlucoseMaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologyEndocrinologyAtorvastatinMedicineRosuvastatin CalciumMetabolic SyndromeSulfonamidesAnticholesteremic AgentsFastingMiddle AgedDrug CombinationsTreatment OutcomeTolerabilityCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyDrug Administration ScheduleEzetimibeDouble-Blind MethodDiabetes mellitusInternal MedicineHumansRosuvastatinPyrrolescardiovascular diseasesAgedApolipoproteins Bbusiness.industrynutritional and metabolic diseasesCholesterol LDLmedicine.diseaseFluorobenzenesDiabetes Mellitus Type 1PyrimidinesDiabetes Mellitus Type 2SimvastatinHeptanoic AcidsAzetidinesMetabolic syndromebusinessDiabetic AngiopathiesDiabetes, obesitymetabolism
researchProduct

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

2020

Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…

Coronavirus COVID-19 Pneumonia SARS-CoV-2 TocilizumabGCA Giant cell arteritispJIA Pediatric juvenile idiopathic arthritislaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineClinical efficacyCPAP Continuous positive airway pressureCOVID-19 Coronavirus disease 2019IDSA Infectious Diseases Society of AmericaRA Rheumatoid arthritisTocilizumabIMV Invasive mechanical ventilationsJIA Juvenile idiopathic arthritisAIFA Agenzia Italiana del FarmacoPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEAntibodies Monoclonal HumanizedNIH U.S. National Institutes of HealthArticleWHO World Health OrganizationSIMIT Italian Society of Infectious and Tropical disease03 medical and health sciencesTocilizumabARDS Acute respiratory distress syndromeAnimalsHumansIn patientIntensive care medicineTocilizumab ; COVID-19 ; Pneumonia ; SARS-CoV-2 ; Coronaviruslcsh:RC705-779business.industryCRS CAR-T cell-induced cytokine release syndromeInterleukin-6SARS-CoV-2NIV Noninvasive mechanical ventilationTNF Tumor necrosis factorCOVID-19Pneumonialcsh:Diseases of the respiratory systemCOVID-19 Drug TreatmentClinical trialCoronavirus030228 respiratory systemchemistrybusinessICTRP International Clinical Trials Registry PlatformPulmonology
researchProduct

Anti-inflammatory properties of simvastatin on leukocyte-endothelial cell interactions following hemorrhagic shock

2002

Background Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been shown to lower serum cholesterol levels. Recent studies reported that statins have vasculoprotective effects independent of their cholesterol-lowering properties. We studied simvastatin for its ability to modulate leukocyte-endothelial cell interactions under acute inflammation following hemorrhage and reperfusion. Methods The effects of simvastatin on leukocyte-endothelial cell interactions were observed by intravital microscopy in the rat mesenteric microcirculation and by immunohistochemical analyzes. Simvastatin (50 μg/kg or 100 μg/kg) was administrated intraperitoneally 18 h before study. Inf…

EndotheliumP-selectinbusiness.industryLeukocyte RollingEmergency NursingPharmacologyCritical Care and Intensive Care MedicineMicrocirculationEndothelial stem cellThrombinmedicine.anatomical_structureSimvastatinImmunologyEmergency Medicinemedicinelipids (amino acids peptides and proteins)businessIntravital microscopymedicine.drugIntensivmedizin und Notfallmedizin
researchProduct

Ezetimibe with or without simvastatin increases small dense low-density lipoproteins in healthy men – a randomized trial

2010

Ezetimibe simvastatin small dense low-density lipoproteins
researchProduct

Effect of simvastatin on desaturase activities in liver from lean and obese zucker rats

1993

The effect of simvastatin, a hypocholesterolemic drug, on the biosynthesis of arachidonic acid was studied in obese and lean Zucker rats. After administration of 2 mg/kg body weight/d for 13 d, delta 6 and delta 5 desaturase activities were measured in liver microsomes at two substrate concentrations. In untreated rats, the delta 6 desaturation rate was similar in the obese and lean rats when measured at saturating substrate levels, whereas delta 5 desaturation was lower in the obese animals. Treatment with simvastatin did not change delta 6 desaturation in either phenotype but increased delta 5 desaturation in obese rats to reach the unchanged rate observed in lean animals. The changes wer…

Fatty Acid DesaturasesMaleSimvastatinmedicine.medical_specialtyClinical chemistryIn Vitro TechniquesBiologyLinoleoyl-CoA DesaturaseBiochemistrychemistry.chemical_compoundDelta-5 Fatty Acid DesaturaseInternal medicinemedicineAnimalsLovastatinObesityPhospholipidschemistry.chemical_classificationAnticholesteremic AgentsFatty AcidsOrganic ChemistryMetabolic disordernutritional and metabolic diseasesFatty acidCell Biologymedicine.diseaseHydroxymethylglutaryl-CoA reductaseRatsRats ZuckerEndocrinologychemistrySimvastatinFatty Acids UnsaturatedMicrosomes LiverMicrosomeArachidonic acidLipidologymedicine.drugLipids
researchProduct